NASDAQ:CYAN Cyanotech (CYAN) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free CYAN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.30▼$0.3050-Day Range$2.83▼$3.2652-Week Range$2.37▼$6.29Volume505 shsAverage Volume4,632 shsMarket Capitalization$2.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsEarningsHeadlinesInsider TradesShort InterestSocial MediaStock AnalysisCompetitorsEarningsHeadlinesInsider TradesShort InterestSocial Media Get Cyanotech alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Cyanotech Stock (NASDAQ:CYAN)Cyanotech Corp. engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.Read More Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> CYAN Stock News HeadlinesApril 18, 2024 | finance.yahoo.comAstaxanthin Market size worth $ 92.81 Billion, Globally, by 2031 at 2.38% CAGR – Report By Verified Market Research®February 26, 2024 | nasdaq.comCYANOTECH CORP. DL-02 (JC7A)April 26, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.February 9, 2024 | finance.yahoo.comCyanotech Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.095 loss in 3Q 2023)February 1, 2024 | finance.yahoo.comGlobal Thermostat commissions first containerized T-Series system for multi-tonne Direct Air Capture of carbon dioxideJanuary 25, 2024 | finance.yahoo.comAstaxanthin Market to Surpass US$ 12.3 Billion in 2032, Forecasting a 21.6% CAGR | Persistence Market ResearchDecember 23, 2023 | finance.yahoo.comOne Cyanotech Insider Raised Stake By 42% In Previous YearNovember 8, 2023 | msn.comCyanotech GAAP EPS of -$0.13, revenue of $6.37MApril 26, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.November 8, 2023 | finance.yahoo.comCyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2024October 11, 2023 | benzinga.comAlgae Fats Market 2031 | Global Leading Countries, Companies, Drivers, Significant Growth, Analysis by Manufacturers, Challenges and Forecast 2031October 9, 2023 | benzinga.comAlgae Supplements Market Is Expected to Reach a Valuation of US$ 2.07 Billion by 2033 : Fact.MR ReportSeptember 26, 2023 | bizjournals.comHawaii aquaculture sales reach record highAugust 11, 2023 | markets.businessinsider.comCyanotech Corp Q1 Loss ClimbsAugust 11, 2023 | finance.yahoo.comCyanotech Reports Financial Results for the First Quarter of Fiscal 2024June 29, 2023 | finance.yahoo.comQ4 2023 Cyanotech Corp Earnings CallJune 29, 2023 | finance.yahoo.comCyanotech Full Year 2023 Earnings: US$0.55 loss per share (vs US$0.35 profit in FY 2022)June 27, 2023 | seekingalpha.comCyanotech GAAP EPS of -$0.55, revenue of $23.18MJune 27, 2023 | finance.yahoo.comCyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2023June 22, 2023 | marketwatch.comUnveiling the Industry Trends: A Comprehensive Marine Algae Products Market Research Study with a Projected 11% during 2023-2030June 5, 2023 | uk.finance.yahoo.comThe Global Sexual Enhancement Supplements MarketMay 17, 2023 | marketwatch.comAnalyzing the Algal Protein Market Size 2023: Drivers and RestraintsMay 17, 2023 | marketwatch.comCarotenoids Market Size Share Cost Structure Analysis And Forecast To 2030May 17, 2023 | marketwatch.com2023 "Natural Astaxanthin Market" Key Manufacturers and Regional Outlook 2031May 16, 2023 | marketwatch.com2023, Marine Bio Products Market Research | 2030May 16, 2023 | marketwatch.com2023, Microalgae Market Research | 2030May 16, 2023 | marketwatch.comSize of Microalgae Market to Grow at 4.5% CAGR and Reach $4996.8 Million by 2027: Brandessence Market ResearchSee More Headlines Receive CYAN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyanotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/08/2024Today4/26/2024Next Earnings (Estimated)6/25/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & botanicals Sub-IndustryN/A Current SymbolNASDAQ:CYAN CUSIPN/A CIK768408 Webwww.cyanotech.com Phone(808) 326-1353Fax808-329-4533Employees95Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,440,000.00 Net Margins-20.52% Pretax Margin-20.48% Return on Equity-30.97% Return on Assets-16.17% Debt Debt-to-Equity Ratio0.07 Current Ratio1.44 Quick Ratio0.37 Sales & Book Value Annual Sales$23.18 million Price / Sales0.09 Cash FlowN/A Price / Cash FlowN/A Book Value$2.61 per share Price / Book0.12Miscellaneous Outstanding Shares6,950,000Free Float5,197,000Market Cap$2.09 million OptionableNot Optionable Beta0.28 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesGerald R. CysewskiVice Chairman & Chief Executive OfficerMatthew CusterPresidentGlenn D. JensenVice President-OperationsFelicia LadinCFO, Treasurer, VP-Finance & AdministrationCharles J. HartmannSenior Sales & Marketing DirectorKey CompetitorsAkandaNASDAQ:AKANSmart for LifeNASDAQ:SMFLIM CannabisNASDAQ:IMCCNanoVibronixNASDAQ:NAOVAclarionNASDAQ:ACONView All CompetitorsInsidersMichael A / DavisBought 3,245 shares on 9/15/2023Total: $2,725.80 ($0.84/share)Michael A / DavisBought 3,245 shares on 9/13/2023Total: $2,693.35 ($0.83/share)Michael A / DavisBought 292 shares on 9/11/2023Total: $242.36 ($0.83/share)Michael A / DavisBought 17,900 shares on 9/7/2023Total: $13,425.00 ($0.75/share)View All Insider Transactions CYAN Stock Analysis - Frequently Asked Questions When is Cyanotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 25th 2024. View our CYAN earnings forecast. How were Cyanotech's earnings last quarter? Cyanotech Co. (NASDAQ:CYAN) announced its quarterly earnings results on Thursday, February, 8th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter. The biotechnology company earned $5.58 million during the quarter. Cyanotech had a negative net margin of 20.52% and a negative trailing twelve-month return on equity of 30.97%. What is Brent D. Bailey's approval rating as Cyanotech's CEO? 6 employees have rated Cyanotech Chief Executive Officer Brent D. Bailey on Glassdoor.com. Brent D. Bailey has an approval rating of 68% among the company's employees. 62.0% of employees surveyed would recommend working at Cyanotech to a friend. What other stocks do shareholders of Cyanotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cyanotech investors own include Allena Pharmaceuticals (ALNA), Clarivate (CCC), Gilead Sciences (GILD), Madrigal Pharmaceuticals (MDGL), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), AcelRx Pharmaceuticals (ACRX), Amarin (AMRN), Blackrock Resources & Commodities Strategy Trust (BCX) and Bausch Health Companies (BHC). This page (NASDAQ:CYAN) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyanotech Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
